drugset / Trial / NCT02244827
Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment
NaSingle-groupOpen-labelBasic science
Summary
This study is aimed to compare the pharmacokinetics of levonadifloxacin and its sulfate metabolite after a single dose of oral WCK 2349 1000 mg in patients with hepatic impairment and healthy volunteers.
Timeline
- Start
- 2014-09
- Primary completion
- 2014-12
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levonadifloxacin | Small molecule | 1000 mg | Oral |